Given that ZDHHC3 mediates B7-H4 palmitoylation, palmitoylation stabilizes total and cell membrane B7-H4 expression, and B7-H4 is degraded in lysosome, we suggest two alternatives to target B7-H4 for cancer immunotherapy. The gene discussed is VTCN1; the disease is cancer.